Assignee
CARIBOU BIOSCIENCES INC
US·60 granted patents·32 pending applications·673 citations·filing 2014–2025
Top patents by PatentIndex Score
92 records- 0199US9816093B1Engineered nucleic acid-targeting nucleic acidsCARIBOU BIOSCIENCES INC·Filed 2016·Granted Nov 14, 2017·69 cites·20 claims
- 0299US9816081B1Engineered nucleic-acid targeting nucleic acidsCARIBOU BIOSCIENCES INC·Filed 2017·Granted Nov 14, 2017·29 cites·20 claims
- 0399US9745562B2Methods of using engineered nucleic-acid targeting nucleic acidsCARIBOU BIOSCIENCES INC·Filed 2017·Granted Aug 29, 2017·32 cites·20 claims
- 0499US9677090B2Engineered nucleic-acid targeting nucleic acidsCARIBOU BIOSCIENCES INC·Filed 2016·Granted Jun 13, 2017·29 cites·20 claims
- 0598US10125361B2Compositions and methods of nucleic acid-targeting nucleic acidsCARIBOU BIOSCIENCES INC·Filed 2016·Granted Nov 13, 2018·24 cites·20 claims
- 0698US9809814B1Compositions and methods of nucleic acid-targeting nucleic acidsCARIBOU BIOSCIENCES INC·Filed 2017·Granted Nov 7, 2017·24 cites·20 claims
- 0798US9803194B2Compositions and methods of nucleic acid-targeting nucleic acidsCARIBOU BIOSCIENCES INC·Filed 2016·Granted Oct 31, 2017·29 cites·22 claims
- 0898US9725714B2Compositions and methods of nucleic acid-targeting nucleic acidsCARIBOU BIOSCIENCES INC·Filed 2016·Granted Aug 8, 2017·29 cites·20 claims
- 0998US9410198B2Compostions and methods of nucleic acid-targeting nucleic acidsCARIBOU BIOSCIENCES INC·Filed 2015·Granted Aug 9, 2016·49 cites·20 claims
- 1098US9260752B1Compositions and methods of nucleic acid-targeting nucleic acidsCARIBOU BIOSCIENCES INC·Filed 2014·Granted Feb 16, 2016·88 cites·12 claims
- 1197US10781432B1Engineered cascade components and cascade complexesCARIBOU BIOSCIENCES INC·Filed 2020·Granted Sep 22, 2020·15 cites·20 claims
- 1297US9909122B2Compositions and methods of nucleic acid-targeting nucleic acidsCARIBOU BIOSCIENCES INC·Filed 2015·Granted Mar 6, 2018·23 cites·19 claims
- 1397US9580727B1Compositions and methods of engineered CRISPR-Cas9 systems using split-nexus Cas9-associated polynucleotidesCARIBOU BIOSCIENCES INC·Filed 2015·Granted Feb 28, 2017·19 cites·19 claims
- 1496US11459588B2Methods of use of CRISPR CPF1 hybrid DNA/RNA polynucleotidesCARIBOU BIOSCIENCES INC·Filed 2021·Granted Oct 4, 2022·2 cites·12 claims
- 1596US10329547B1Engineered cascade components and cascade complexesCARIBOU BIOSCIENCES INC·Filed 2019·Granted Jun 25, 2019·12 cites·20 claims
- 1696US9771600B2Engineered nucleic acid-targeting nucleic acidsCARIBOU BIOSCIENCES INC·Filed 2016·Granted Sep 26, 2017·11 cites·20 claims
- 1796US9745600B2Compositions and methods of engineered CRISPR-Cas9 systems using split-nexus Cas9-associated polynucleotidesCARIBOU BIOSCIENCES INC·Filed 2016·Granted Aug 29, 2017·9 cites·21 claims
- 1895US10988781B2Method of target cleaving using CRISPR hybrid DNA/RNA polynucleotidesCARIBOU BIOSCIENCES INC·Filed 2020·Granted Apr 27, 2021·2 cites·9 claims
- 1995US9885026B2Modified cascade ribonucleoproteins and uses thereofCARIBOU BIOSCIENCES INC·Filed 2016·Granted Feb 6, 2018·34 cites·6 claims
- 2094US11142583B2BCMA-CAR-natural killer (NK) cells and methods related theretoCARIBOU BIOSCIENCES INC·Filed 2021·Granted Oct 12, 2021·2 cites·16 claims
- 2194US10227576B1Engineered cascade components and cascade complexesCARIBOU BIOSCIENCES INC·Filed 2018·Granted Mar 12, 2019·66 cites·20 claims
- 2294US10138472B2Engineered nucleic-acid targeting nucleic acidsCARIBOU BIOSCIENCES INC·Filed 2018·Granted Nov 27, 2018·4 cites·20 claims
- 2394US10125354B1Engineered nucleic-acid targeting nucleic acidsCARIBOU BIOSCIENCES INC·Filed 2018·Granted Nov 13, 2018·4 cites·20 claims
- 2494US10023853B1Engineered nucleic-acid targeting nucleic acidsCARIBOU BIOSCIENCES INC·Filed 2018·Granted Jul 17, 2018·4 cites·18 claims
- 2594US9957490B1Cells comprising engineered nucleic-acid targeting nucleic acidsCARIBOU BIOSCIENCES INC·Filed 2017·Granted May 1, 2018·4 cites·20 claims
- 2693US11472884B2Humanized BCMA antibody and BCMA-CAR-T cellsCARIBOU BIOSCIENCES INC·Filed 2022·Granted Oct 18, 2022·2 cites·13 claims
- 2793US11021542B1Humanized BCMA antibody and BCMA-CAR-T cellsCARIBOU BIOSCIENCES INC·Filed 2021·Granted Jun 1, 2021·2 cites·20 claims
- 2893US9970026B2Compositions and methods of engineered CRISPR-Cas9 systems using split-nexus Cas9-associated polynucleotidesCARIBOU BIOSCIENCES INC·Filed 2017·Granted May 15, 2018·4 cites·20 claims
- 2993US9970027B2Compositions and methods of engineered CRISPR-CAS9 systems using split-nexus CAS9-associated polynucleotidesCARIBOU BIOSCIENCES INC·Filed 2017·Granted May 15, 2018·4 cites·20 claims
- 3092US11555181B2Engineered cascade components and cascade complexesCARIBOU BIOSCIENCES INC·Filed 2020·Granted Jan 17, 2023·2 cites·19 claims
- 3192US10927182B2Humanized BCMA antibody and BCMA-CAR-T cellsCARIBOU BIOSCIENCES INC·Filed 2020·Granted Feb 23, 2021·2 cites·18 claims
- 3292US10100333B2Engineered nucleic acid-targeting nucleic acidsCARIBOU BIOSCIENCES INC·Filed 2018·Granted Oct 16, 2018·4 cites·20 claims
- 3392US9970029B1Engineered nucleic acid-targeting nucleic acidsCARIBOU BIOSCIENCES INC·Filed 2017·Granted May 15, 2018·4 cites·20 claims
- 3491US10954498B2Modified cascade ribonucleoproteins and uses thereofCARIBOU BIOSCIENCES INC·Filed 2020·Granted Mar 23, 2021·2 cites·13 claims
- 3591US10457922B1Engineered cascade components and cascade complexesCARIBOU BIOSCIENCES INC·Filed 2019·Granted Oct 29, 2019·4 cites·22 claims
- 3691US10196619B1Engineered nucleic-acid targeting nucleic acidsCARIBOU BIOSCIENCES INC·Filed 2018·Granted Feb 5, 2019·2 cites·20 claims
- 3790US11299549B2Humanized BCMA antibody and BCMA-CAR-T cellsCARIBOU BIOSCIENCES INC·Filed 2021·Granted Apr 12, 2022·1 cites·22 claims
- 3890US9970030B2Methods for increasing CAS9-mediated engineering efficiencyCARIBOU BIOSCIENCES INC·Filed 2015·Granted May 15, 2018·8 cites·19 claims
- 3989US10711257B2Modified cascade ribonucleoproteins and uses thereofCARIBOU BIOSCIENCES INC·Filed 2019·Granted Jul 14, 2020·2 cites·13 claims
- 4088US11225649B2Engineered nucleic-acid targeting nucleic acidsCARIBOU BIOSCIENCES INC·Filed 2020·Granted Jan 18, 2022·1 cites·14 claims
- 4188US10597648B2Engineered cascade components and cascade complexesCARIBOU BIOSCIENCES INC·Filed 2019·Granted Mar 24, 2020·2 cites·20 claims
- 4288US2024167023A1Compositions and methods of nucleic acid-targeting nucleic acidsCARIBOU BIOSCIENCES INC·Filed 2023·Application pending·0 cites
- 4387US2024174998A1Modified cascade ribonucleoproteins and uses thereofCARIBOU BIOSCIENCES INC·Filed 2024·Application pending·0 cites
- 4486US10125375B2Methods of modifying a target nucleic acid with an ArgonauteCARIBOU BIOSCIENCES INC·Filed 2017·Granted Nov 13, 2018·3 cites·15 claims
- 4586US2023193324A1Crispr hybrid dna/rna polynucleotides and methods of useCARIBOU BIOSCIENCES INC·Filed 2022·Application pending·0 cites
- 4685US11236364B2CRISPR hybrid DNA/RNA polynucleotides and methods of useCARIBOU BIOSCIENCES INC·Filed 2019·Granted Feb 1, 2022·2 cites·21 claims
- 4785US10435678B2Modified cascade ribonucleoproteins and uses thereofCARIBOU BIOSCIENCES INC·Filed 2017·Granted Oct 8, 2019·3 cites·11 claims
- 4885US9902973B2Methods of modifying a target nucleic acid with an argonauteCARIBOU BIOSCIENCES INC·Filed 2014·Granted Feb 27, 2018·5 cites·12 claims
- 4984US11111506B2Compositions and methods of engineered CRISPR-Cas9 systems using split-nexus Cas9-associated polynucleotidesCARIBOU BIOSCIENCES INC·Filed 2018·Granted Sep 7, 2021·1 cites·20 claims
- 5083US12492264B2Anti-ROR1 antibody and ROR1-targeting engineered cellsCARIBOU BIOSCIENCES INC·Filed 2024·Granted Dec 9, 2025·0 cites·9 claims
Showing the top 50 of 92 patent records by PatentIndex Score.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →